Twist Bioscience Corporation

NASDAQ:TWST

Medical - Diagnostics & Research

Healthcare
$116.35 +2.59%

+$2.15 today

Market cap
$7.66B
Beta
2.21
P/E (TTM)
-64.5
EPS (TTM)
-$1.32
52W Low $23.30High $88.46

Volume 2.23M

Average 1.53M

TWST Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Twist Bioscience CorporationNASDAQ: TWST

Operating Expenses · Q4 FY2026 · quarter ended Sep 2026

Operating expenses growth accelerates

Q4 FY2026 operating expenses of $98.87M rose 22.4% year over year, ahead of the +16.2% change in trailing-twelve-month operating expenses. Sequentially, it rose 0.1% from the prior quarter. Over 3 fiscal years it compounded at +7.4% a year.

Context

  • Operating expenses amounted to 82.8% of revenue in FY2026, down 4.1 pp from a year earlier.
  • Operating expenses increased in 2 of the last 3 fiscal years.
  • FY2026 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +22.4% holds above the trailing-twelve-month pace of +16.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$98.87M+0.1% QoQ
Last fiscal yearSep 2026
$380.26M+16.2% YoY
LTMSep 2026
$380.26M+16.2% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+22.4%——
1 year+16.2%——
3-year CAGR+7.4%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2026
380.26M USD
Year-over-year change
+16.2%
4-year CAGR
+4.5%

Operating Expenses vs competitors

How TWST compares with its peers on the latest reported figures

  • TWST's LTM Sep 2026 operating expenses of $380.26M is the highest of the 2 companies compared; the peer median is $335.5M.
  • Its year-over-year change of +16.2% is the highest of 2, against a peer median of +4.2%.
  • Operating expenses amounts to 82.8% of revenue for TWST, versus a peer median of 42.7%.
TWST Competitors Peer median
Operating Expenses for TWST and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TWSTTwist Bioscience CorporationLTM Sep 2026$380.26M +16.2%+7.4%82.8%
RGENRepligen CorporationLTM Jun 2026$335.5M +4.2%+7.6%42.7%
Peer median (excluding TWST) $335.5M+4.2%+7.6%42.7%

Competitors are the stored peer set for TWST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
FY2026
Sep 2026
Revenue203.57M245.11M312.97M376.57M459.43M
Cost of Revenue119.33M155.38M179.63M185.57M218.63M
Gross Profit84.24M89.73M133.35M191M240.8M
Gross Margin41.4%36.6%42.6%50.7%52.4%
Research & Development120.31M106.89M90.85M80.29M71.84M
Selling, General & Admin212.95M189.74M218.4M246.98M301.22M
Operating Expenses319.01M306.89M354.18M327.26M380.26M
Depreciation & Amortization16.51M29.31M31.43M24.85M0
EBITDA(211.68M)(174.15M)(176.71M)(52.1M)(129.8M)
EBITDA Margin-104.0%-71.1%-56.5%-13.8%-28.3%
Operating Income(234.78M)(217.16M)(220.83M)(136.26M)(139.46M)
Operating Margin-115.3%-88.6%-70.6%-36.2%-30.4%
Interest Income3.06M14.37M15.34M11.36M8.8M
Interest Expense80K5K29K00
Other Income / Expenses6.5M13.69M12.67M59.31M8.85M
Income Before Tax(228.27M)(203.47M)(208.17M)(76.95M)(130.61M)
Pre-Tax Margin-112.1%-83.0%-66.5%-20.4%-28.4%
Income Tax Expense(10.41M)1.15M560K719K(406K)
Net Income(217.86M)(204.62M)(208.73M)(77.67M)(130.2M)
Net Margin-107.0%-83.5%-66.7%-20.6%-28.3%
EPS (Basic)(4.04)(3.60)(3.60)(1.30)(2.08)
EPS (Diluted)(4.04)(3.60)(3.60)(1.30)(2.08)
Weighted Avg Shares53.89M56.89M58.02M59.81M62.62M
Weighted Avg Shares (Diluted)53.89M56.89M58.02M59.81M62.62M

Twist Bioscience Corporation

NASDAQ:TWST

Intrinsic Alpha fair value

Locked

Current Price

$116.35

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.